OncoMatch/Clinical Trials/NCT07266441
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Is NCT07266441 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies JNJ-79635322 for multiple myeloma.
Treatment: JNJ-79635322 — The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
Must have received: immunomodulatory drug
Must have received: anti-cd38 monoclonal antibody
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- City of Hope Orange County Lennar Foundation Cancer Center · Irvine, California
- Cancer and Blood Specialty Clinic · Los Alamitos, California
- Cancer Specialists of North Florida · Jacksonville, Florida
- Emory University · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07266441 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received proteasome inhibitor and immunomodulatory drug.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages